Among patients with T2D and DPN, some with nonpainful DPN developed neuropathic pain over a 5-year period while others with painful DPN experienced relief.

Medically reviewed by Christopher Lee, MD Treatment for ATTR-CM has historically been symptom management. However, until 2019, the United States Food and Drug Administration (FDA) did not approve any ...

Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for ...

People with any type of substance use disorder (SUD) stand a 24% higher risk of having an unplanned hospital readmission ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Medicines and Healthcare products Regulatory Agency ...

Morgan Stanley expects a “normal” earnings beat rate for the second quarter, with S&P 500 EPS growth forecast at 5% year-over-year and sales up 4%.

Grifols revises forecasts upward after strong Q1, targeting €10B sales and €2.9B EBITDA. Click here to read my analysis of ...

People with any type of substance use disorder (SUD) stand a 24% higher risk of having an unplanned hospital readmission within 30 days of a previous discharge compared with those without the disorder ...

US FDA grants fast track designation to Sanofi’s SAR446597 to treat geographic atrophy due to age-related macular degeneration: Paris Thursday, July 17, 2025, 10:00 Hrs [IST] Th ...

Other medications, such as gabapentin, venlafaxine, and certain sodium channel blockers, are also sometimes used for nerve ...